BlueRock Collaborates with Fujifilm and Opsis to Discover and Develop Cell Therapies for Eye Diseases

 BlueRock Collaborates with Fujifilm and Opsis to Discover and Develop Cell Therapies for Eye Diseases

BlueRock Collaborates with Fujifilm and Opsis to Discover and Develop Cell Therapies for Eye Diseases

Shots:

  • Fujifilm and Opsis to receive $30M up front and ~$40M as R&D and part of manufacturing funding for the development of 3 programs. The companies are eligible to receive development & commercial milestones along with royalties on a per-program basis
  • BlueRock to get an option to license the 3 programs on a program-by-program basis and will be responsible for development & commercialization of the licensed products. Fujifilm and BlueRock will share manufacturing responsibilities and commercial supply, with Fujifilm responsible for clinical supply
  • The companies will combine their expertise to discover and develop off-the-shelf iPS cell therapies for ocular diseases

Click here to­ read full press release/ article | Ref: Bayer | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post